SSA
CRNX icon

Schonfeld Strategic Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-81,847
Closed -$3.41M – 2132
2025
Q3 		$3.41M Sell
81,847
-66,076
-45% -$2.11M 0.02% 770
2025
Q2 		$4.25M Buy
147,923
+128,731
+671% +$3.98M 0.03% 618
2025
Q1 		$644K Sell
19,192
-426,754
-96% -$15.9M ﹤0.01% 1475
2024
Q4 		$22.8M Sell
445,946
-44,779
-9% -$2.51M 0.13% 131
2024
Q3 		$25.1M Sell
490,725
-162,832
-25% -$8.4M 0.17% 94
2024
Q2 		$29.3M Buy
653,557
+518,264
+383% +$23.9M 0.19% 100
2024
Q1 		$6.33M Buy
135,293
+68,000
+101% +$2.66M 0.04% 551
2023
Q4 		$2.39M Sell
67,293
-209,915
-76% -$6.44M 0.02% 741
2023
Q3 		$8.24M Buy
+277,208
New +$5.71M 0.06% 403
2023
Q2 		– Sell
-73,890
Closed -$1.19M – 2199
2023
Q1 		$1.19M Buy
+73,890
New +$1.37M 0.01% 884
2022
Q1 		– Sell
-18,600
Closed -$528K – 2641
2021
Q4 		$528K Sell
18,600
-2,900
-13% -$71.5K ﹤0.01% 1234
2021
Q3 		$453K Sell
21,500
-300
-1% -$6.28K ﹤0.01% 1320
2021
Q2 		$411K Buy
+21,800
New +$383K ﹤0.01% 1288

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Schonfeld Strategic Advisors's CRNX Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 81,847 shares — an estimated $3.41M sold.

Schonfeld Strategic Advisors first reported a position in CRNX in Q2 2021 and held it in 13 quarters. The position peaked at $29.3M in Q2 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 81,847 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $3.41M.
  • Schonfeld Strategic Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2021 and held it in 13 quarters.
  • Schonfeld Strategic Advisors's Crinetics Pharmaceuticals position peaked at $29.3M in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.